空腹三酰甘油水平对急性ST段抬高型心肌梗死患者远期预后的影响

陈凤敏; 郑杨; 高明; 许慧娟

doi:10.13201/j.issn.1001-1439.2019.05.006

空腹三酰甘油水平对急性ST段抬高型心肌梗死患者远期预后的影响

- 吉林大学第一医院心内科(长春, 130021)

详细信息

通讯作者: 郑杨,E-mail:zhengyanghappy07@sina.com

中图分类号: R541.4

收稿日期: 2018-11-23

Effect of fasting triglyceride level on long-term prognosis of patients with acute ST-segment elevation myocardial infarction

- Department of Cardiology, The First Hospital of Jilin University, Changchun, 130021, China

More Information

Corresponding author: ZHENG Yang, E-mail: zhengyanghappy07@sina.com

Received Date: 23 November 2018

摘要

摘要: 目的：探讨入院空腹三酰甘油（FTG）水平与急性ST段抬高型心肌梗死（STEMI）后行经皮冠状动脉介入治疗（PCI）术后患者远期预后的相关性。方法：连续入选就诊于我院的1 125例PCI术后STEMI患者，术后对所有患者进行电话随访18个月，收集主要心脑血管事件（MACCE）发生情况。根据是否死亡将患者分为死亡组（49例）与存活组（994例），比较两组各临床指标差异，采用COX多因素分析心源性死亡与全因死亡的独立危险因素。结果：年龄、住院天数、左心室射血分数（LVEF）、Killip分级、尿素氮（BUN）、肌酐（Cr）、谷丙转氨酶（ALT）、谷草转氨酶（AST）、FTG、空腹血糖（FBG）在死亡组与生存组间均差异有统计学意义（均P<0.05）。多因素分析显示，就诊年龄与FTG水平是STEMI患者18个月心源性死亡、全因死亡的独立危险因素。Kaplan-Meier生存分析结果显示，不同FTG水平患者间心源性死亡、全因死亡无显著差异。结论：FTG水平与就诊年龄是急性STEMI患者18个月心源性死亡与全因死亡的独立危险因素。
- 急性ST段抬高型心肌梗死 /
- 三酰甘油 /
- 经皮冠状动脉介入治疗
Abstract: Objective: To study the relationship between fasting triglyceride (FTG) level and long-term prognosis of patients with acute ST segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI).Method: A total of 1125 patients with STEMI after PCI were enrolled.All patients were followed up by telephone for 18 months.Main cardiovascular and cerebrovascular events (MACCEs) were collected.Patients were divided into death group (n=49) and survival group (n=994).The differences of clinical indicators between the two groups were compared.The independent risk factors of cardiogenic death and all-cause death were analyzed by COX multivariate analysis.Result: Age, hospitalization time, left ventricular ejection fraction (LVEF), Killip classification, urea nitrogen (BUN), creatinine (Cr), alanine aminotransferase (ALT), glutamic oxaloacetic aminotransferase (AST), FTG and fasting blood glucose (FBG) were significantly different between death group and survival group.Multivariate analysis showed that age and FTG level were independent risk factors for cardiogenic and all-cause death in 18 months.Kaplan-Meier survival analysis showed that there was no significant difference in cardiogenic and all-cause mortality among groups with different FTG levels (PLog-Rank > 0.05).Conclusion: FTG level and age are independent risk factors of cardiac death at 18 months in patients with acute STEMI.
- fasting triglyceride /
- acute ST segment elevation myocardial infarction /
- percutaneous coronary intervention

HTML全文

参考文献(18)

[1]	邵启文, 刘长梅.急性ST段抬高型心肌梗死患者mCRP、GAS与冠状动脉病变程度相关性研究[J].临床心血病杂志, 2017, 33(9):862-865.
[2]	谭文鹏, 李文杰.强化瑞舒伐他汀对急性ST段抬高型心肌梗死患者8-OHdG和ESM-1水平的影响及预后观察[J].临床心血病杂志, 2018, 34(2):127-131.
[3]	Thygesen K, Alpert JS, Jaffe AS, et al.Fourth universal definition of myocardial infarction (2018)[J].Euro Heart J, 2019, 40(3):237-269.
[4]	中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志, 2016, 31(10):937-953.
[5]	Lin A, Nerlekar N, Rajagopalan A, et al.Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography[J].Atherosclerosis, 2019, 284:24-30.
[6]	Sarwar N, Danesh J, Eiriksdottir G, et al.Triglycerides and the risk of coronary heart disease:10, 158 incident cases among 262, 525 participants in 29 Western prospective studies[J].Circulation, 2007, 115(4):450-458.
[7]	Werner C, Filmer A, Fritsch M, et al.Prediction with triglycerides in patients with stable coronary disease on statin treatment[J].Clin Res Cardiol, 2014, 103(12):984-997.
[8]	Rosenson RS, Davidson MH, Hirsh BJ, et al.Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease[J].JACC, 2014, 64(23):2525-2540.
[9]	Matthew J, Allan Sniderman, et al.Apolipoprotein B, apoA-I, triglycerides and glucose-a powerful combination of cardiac risk predictors[J].Diabetologia, 2003, 46(2):A73-A75.
[10]	Do R, Willer CJ, Schmidt EM, et al.Common variants associated with plasma triglycerides and risk for coronary artery disease[J].Nat Genet, 2013, 45(11):1345-1352.
[11]	Rosenson RS, Davidson MH, Hirsh BJ, et al.Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease[J].JACC, 2014, 64(23):2525-2540.
[12]	Ramms S, Gordts PLSM.Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism[J].Curr Opin Lipidol, 2018, 29(3):171-179.
[13]	Bansal S, Buring JE, Rifai N, et al.Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women[J].JAMA, 2007, 298(3):309-316.
[14]	Lindman AS, Veierød MB, Tverdal A, et al.Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study[J].Eur J Epidemiol, 2010, 25(11):789-798.
[15]	Kang K, Lee JJ, Park JM, et al.High nonfasting triglyceride concentrations predict good outcome following acute ischaemic stroke[J].Neurol Res, 2017, 39(9):779-786.
[16]	Ariafar M, Dashti F, et al.Relationship Between the Serum Levels of Nonfasting Triglyceride and the Severity of Coronary Artery Disease[J], Iranian Heart J, 2018, 19(1):21-29.
[17]	Jørgensen AB, Frikke-Schmidt R, West AS, et al.Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction[J].Eur Heart J, 2013, 34(24):1826-1833.
[18]	Catapano AL, Graham I, De Backer G, et al.2016 ESC/EAS Guidelines for the management of dyslipidaemias[J].Eur Heart J, 2016, 37(39):272-387.